Ken Song

Biotech entrepreneur and CEO of Candid Therapeutics, previously CEO of Raise Bio which was acquired by Bristol Myers Squibb; leading development of bispecific T-cell engaging antibodies for autoimmune disease.

Best podcasts with Ken Song

Ranked by the Snipd community

Mar 3, 2026 • 1h 6min

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ken Song, biotech entrepreneur and CEO of Candid Therapeutics, previously led Raise Bio to acquisition by Bristol Myers Squibb. He discusses developing bispecific T-cell engaging antibodies for autoimmune disease. Topics include why T-cell engagers may mimic CAR-T effects more safely, licensing clinical-stage assets from China, regulatory and geographic strategy for rapid trials, and choosing indications to hunt for broad immune-reset signals.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app